Teleflex

Teleflex, Inc. provides medical technology products which enables healthcare providers to improve patient outcomes and enhance patient and provider safety. The firm designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates through the following business segments: Americas, EMEA (Europe, the Middle East and Africa), Asia (Asia Pacific) and OEM. The Americas segment engages in the sales of interventional urology products. The EMEA engages in the sales of urology products. The Asia segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and cardiac care and generally serves hospitals and healthcare providers. The OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. The company was founded in 1943 and is headquartered in Wayne, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teleflex reports Q4 growth amidst challenges, eyes revenue acceleration

Teleflex's Q4 performance showed resilience with revenue growth and strategic acquisitions. While facing challenges like supply chain disruptions and UroLift revenue decline, the company is focused on margin expansion and disciplined growth. Opportunities lie in revenue acceleration, international expansion, and leveraging high-growth product categories.

Teleflex reports robust Q1 earnings, eyes growth amid challenges

Teleflex's Q1 2023 results reflect strong performance and strategic focus on sustainable growth, supported by geographic revenue growth and product category contributions.
While facing challenges in specific product lines and supply chain issues, the company maintains a disciplined approach to deals and cost management.
Opportunities lie in revised revenue guidance, product performance, and market improvements, positioning Teleflex for continued success in 2023.

Teleflex reports revenue growth and strategic acquisitions drive future outlook

Teleflex revised its 2023 financial guidance with revenue growth of 5.5% to 6.25% and adjusted EPS of $13 to $13.60. Despite challenges in certain product segments, the company remains confident in achieving its Long Range Plan growth objectives. The focus on integrating acquisitions like Palette and leveraging high-growth products positions Teleflex for continued success.

Teleflex reports robust Q3 results, eyes growth amidst challenges

Teleflex's Q3 performance reflects revenue and EPS growth, driven by operational improvements.
Despite challenges from GLP-1 impact and tax rate increases, the company remains optimistic.
Opportunities lie in market expansion, M&A activities, and product uniqueness strategies.
Overall, Teleflex's strong financials and strategic initiatives position it for continued growth.

Teleflex reports solid 2023 performance, eyes growth in Urology market

Teleflex's 2023 performance showed revenue growth and strong cash flow, with guidance for 2024 indicating continued growth and margin targets.
Despite challenges like declining EPS and recall impacts, the company aims for high EPS growth and sees opportunities in new markets and product expansions.
Confidence in meeting targets, pursuing strategic initiatives, and navigating market challenges position Teleflex for growth and profitability in the coming years.
Balancing financial performance with strategic investments and operational improvements will be key for Teleflex to capitalize on growth opportunities and overcome challenges.

Teleflex reports solid Q1 performance, eyes growth through acquisitions

Teleflex's Q1 2024 performance was solid, with revenue growth, margin expansion, and strong cash flow. Despite challenges like market multiples and recall impacts, the company is focused on growth opportunities and disciplined acquisitions to drive future success.

Teleflex reports solid Q2 growth, eyes M&A and product innovation

Teleflex's Q2 performance reflects steady growth, driven by strong results in key segments and product categories.
Despite challenges in certain areas, the company's strategic initiatives, including acquisitions and product innovation, position it well for future success.
With a focus on revenue growth, operational efficiency, and shareholder value, Teleflex is poised to capitalize on opportunities and navigate challenges effectively.

Teleflex reports solid Q3 earnings, eyes growth amid challenges

Teleflex's Q3 2024 performance showcased revenue growth, margin improvement, and strategic acquisitions driving increased revenue guidance for the year.
While facing challenges in specific product categories, the company's focus on innovation, market expansion, and financial strength positions it well for future growth.
Opportunities in expanding markets, disciplined capital allocation, and strong cash flow generation underscore Teleflex's resilience and potential for sustained success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teleflex, Inc. provides medical technology products which enable healthcare providers to improve patient outcomes and enhance patient and provider safety. It operates through the following business segments: Americas, EMEA (Europe, the Middle East and Africa), Asia (Asia Pacific) and OEM. The Americas segment engages in the sales of interventional urology products. The EMEA engages in the sales of urology products. The Asia segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and cardiac care and generally serves hospitals and healthcare providers. The OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. The company was founded in 1943 and is headquartered in Wayne, PA.

The acquisition of Z-Medica and an increase in sales of new products contribute to Teleflex's (TFX) revenue growth in Americas in Q1

Teleflex (TFX) Beats on Q1 Earnings and Revenues, Raises View

Shares of Teleflex (NYSE:TFX) fell 0.3% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 5.51% year over year to $2.87, which beat the estimate of $2.42.

Teleflex: Q1 Earnings Insights

First quarter 2021 revenues of $633.9 million, up 0.5% versus prior year period on an as-reported basis; down 2.6% on a constant currency basis

Teleflex Reports First Quarter 2021 Results

WAYNE, Pa., April 27, 2021 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Bank of America Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021 at 8:00 a.m. (ET).

Teleflex to Present at the Bank of America Securities 2021 Virtual Health Care Conference

Live Webcast is scheduled at 8:00 a.m. (ET) on Thursday, April 29, 2021 Live Webcast is scheduled at 8:00 a.m. (ET) on Thursday, April 29, 2021

Teleflex Announces First Quarter 2021 Earnings Conference Call Information

Teleflex (TFX) reported earnings 30 days ago. What's next for the stock?

Why Is Teleflex (TFX) Up 2.6% Since Last Earnings Report?

WAYNE, Pa.--(BUSINESS WIRE)--UroLift® System, a proven treatment for Benign Prostatic Hyperplasia (BPH), now reimbursed in France

UroLift® System, a proven treatment for Benign Prostatic Hyperplasia (BPH), now reimbursed in France

WAYNE, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Jake Elguicze, Treasurer and Vice President of Investor Relations, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Wednesday, March 24, 2021 at 9:15am (ET).

Teleflex to Present at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

WAYNE, Pa., March 09, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced that, globally, 250,000 patients have been treated with the UroLift® System, a proven, minimally invasive approach to treating benign prostatic hyperplasia (BPH).

Teleflex Reports 250,000 Patients Treated for Enlarged Prostate With the Minimally Invasive UroLift® System

Teleflex (TFX) CEO Liam Kelly on Q4 2020 Results - Earnings Call Transcript

Teleflex (TFX) witnesses significant sequential improvement in segmental performance during the fourth quarter on gradual recovery of the economy.

Teleflex (TFX) Beats on Q4 Earnings and Revenues, Margins Fall

Teleflex (TFX) delivered earnings and revenue surprises of 7.26% and 3.55%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Teleflex (TFX) Beats Q4 Earnings and Revenue Estimates

Fourth quarter 2020 revenues of $711.2 million, up 4.4% versus prior year period on an as-reported basis; up 2.3% on a constant currency basis

Teleflex Reports Fourth Quarter and Full Year 2020 Results; Provides 2021 Guidance

Submission is eligible for priority review and accelerated approval Submission is eligible for priority review and accelerated approval

Teleflex Announces Submission of Biologics License Application for Its Investigational Freeze Dried Plasma

WAYNE, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at Barclays Global Healthcare Conference on Tuesday, March 9, 2021 at 10:55 am (ET).

Teleflex to Present at Barclays Global Healthcare Conference

Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Teleflex (TFX) Q4 Earnings Expected to Decline

Enrollment Completed Ahead of Schedule in Study Evaluating the Performance of Teleflex Specialty Catheters and Coronary Guidewires in Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Interventions Enrollment Completed Ahead of Schedule in Study Evaluating the Performance of Teleflex Specialty Catheters and Coronary Guidewires in Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Interventions

Teleflex Completes Enrollment in CTO-PCI IDE Study

Company ranks as a top employer in the Mid-Size Employer and Health Care Equipment & Services categories Company ranks as a top employer in the Mid-Size Employer and Health Care Equipment & Services categories

Teleflex Named One of America's Best Employers 2021 by Forbes

WAYNE, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Raymond James 42nd Annual Institutional Investors Conference on Tuesday, March 2, 2021 at 12:30 p.m. (ET).

Teleflex to Present at the Raymond James 42nd Annual Institutional Investors Conference

TeleFlex (TFX) Interventional business revenues are down due to the cancellation of certain non-emergent procedures.

TeleFlex (TFX) Organic Sales Hit by COVID-19, Urolift Grows

Live Webcast is scheduled at 8:00 a.m. (ET) on Thursday, February 25, 2021 Live Webcast is scheduled at 8:00 a.m. (ET) on Thursday, February 25, 2021

Teleflex Announces Fourth Quarter and Full Year 2020 Earnings Conference Call Information

WAYNE, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that new data published in the peer-reviewed journal, European Urology Focus , found that men treated with the Prostatic Urethral Lift (PUL) procedure (using the UroLift® System) showed preservation and some improvement of sexual function compared to men being treated with medication for benign prostatic hyperplasia (BPH).

Published Data Demonstrate Sexual Function Improvement and Preservation with the Minimally Invasive UroLift® System Compared to Medications Prescribed for Benign Prostatic Hyperplasia

Teleflex expands value of ErgoPack® Complete enhancements to critical vascular access products Teleflex expands value of ErgoPack® Complete enhancements to critical vascular access products

Teleflex continues to deliver COMPLETE confidence with new Arrow® ErgoPack® Complete MAC, PSI Systems

WAYNE, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 8:20 a.m. (ET).

Teleflex to Present at the 39th Annual J.P. Morgan Healthcare Conference

Teleflex (TFX) to leverage its strength in enhancing clinical efficacy and patient safety via the recent buyout.

News for Teleflex Stock (TFX)